Pulmonary Artery Pressure-Guided Therapy

Device therapy for pulmonary artery-pressure-guided management of patients with HF was beneficial regardless of ejection fraction, according to new data from the GUIDE-HF trial presented at TCT 2021.

Management of patients with HF with or without pulmonary artery pressure information derived from an implantable device (CardioMEMS, Abbott).

The GUIDE-HF trial of hemodynamic-guided management of HF did not meet its primary endpoint, but analyses limited to the period before the COVID-19 pandemic showed benefit in a broader range of patients than previously demonstrated.